Celgene Target Raised Ahead of Q4 Results and 4 Must-See Stock Analyses

NorthStar Realty Finance Corp. (NYSE:NRF): Current Price: $7.45

After it attended a roadshow with Northstar, JMP Securities decided to raise its target on the company due to the firm’s positive view of the company’s joint venture investment in commercial real estate private equity and its new non-traded REIT product. The firm recommends purchasing the stock at current levels.

Capture

Start 2013 better than ever by saving time and making money with your Limited Time Offer for our highly-acclaimed Stock Picker Newsletter. Click here for our fresh Feature Stock Pick now!

Curtiss-Wright Corp. (NYSE:CW): Cirrent Price: $34.42

The company was added to Deutsche Bank’s short-term buy list.

Capture

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.

Dresser-Rand Group Inc. (NYSE:DRC): Current Price: $57.01

Citigroup predicts that it will see an increase in the amount of Oilfield Services & Equipment mergers and acquisition deals during 2013. The firm believes that the most probably takeover candidates are equipment manufacturing and deepwater focused stocks, including Dresser-Rand, Rowan Companies (NYSE:RDC), Lufkin (NASDAQ:LUFK), FMC Technologies (NYSE:FTI), and Forum Energy (FET). Furthermore, Citi added Weatherford (NYSE:WFT) as a prime takeover target for 2013 when considering the recent underperformance of shares.

Capture

Start 2013 better than ever by saving time and making money with your Limited Time Offer for our highly-acclaimed Stock Picker Newsletter. Click here for our fresh Feature Stock Pick now!

CEVA Inc. (NASDAQ:CEVA): Current Price: $16.99

Benchmark Co. continues to be convinced that Q1 estimates for CEVA could potentially be a bit too high, but the firm is convinced that CEVA’s revenue will likely be boosted by improving royalty rates along with more penetration into new markets. The firm keeps its Buy rating on the stock.

Capture

Celgene Corporation (NASDAQ:CELG): Current Price: $97.63

Brean Capital decided to increase its price target on Celgene prior to the company’s Q4 results. The firm predicts that earnings will be in-line with Street expectations, but it also sees compounded earnings over the next three years rising 20 percent based on the potential of the company’s hematology/oncology franchise. Shares have a Buy rating.

Capture

Don’t Miss: Is The London Whale Beached?